Suggestions
Jonathan Northrup
CEO, CoFounder, Board Member at Stingray Therapeutics
Jonathan Northrup is a seasoned executive and entrepreneur in the biotechnology and pharmaceutical industries. He currently serves as a Board Member and Advisor at Vasculonics, a position he has held since September 2020.1
Current Roles
Northrup is also the CEO and Co-founder of Stingray Therapeutics, an immune oncology company he established in June 2018.12 At Stingray Therapeutics, he is focused on developing innovative therapies in the field of immune oncology.1
Other Board Positions
In addition to his roles at Vasculonics and Stingray Therapeutics, Northrup holds several other board positions:
- Board Member at Iterion Therapeutics (since June 2018)
- Board Member and Co-founder at Salarius Pharmaceuticals (since January 2012)1
Previous Experience
Northrup's career in the pharmaceutical and biotechnology industries spans several decades. Some of his previous positions include:
- CEO, Board Member, and Co-founder of Beta Cat Pharmaceuticals (March 2011 - June 2018)
- COO at Jubilant Innovation (January 2007 - March 2011)
- CEO & Founder of Horizon Biotechnologies (2004 - 2006)
- VP of Business Development & Strategy at Eli Lilly (1996 - 2004)1
Education
Northrup holds an MBA from The Wharton School of Business, which he obtained between 1974 and 1976. He also has a Bachelor of Arts (B.A.) from Northwestern University, earned between 1970 and 1974.1
Professional Certification
In 2010, Northrup was awarded the Certified Licensing Professional (CLP) designation by the Licensing Executive Society, recognizing his expertise in business development and licensing.1
Highlights
I just registered for <Conference name>! Join me January 9–11, 2023 in San Francisco for the return of face-to-face meetings during the busiest week in healthcare. https://lnkd.in/gGm9XF_Q Informa Connect
Please help these good people at Vasculonics get a $50,000 cash award by voting for them in this competition!
Dear Jon: I am pleased to inform you that Vasculonics has been selected as a semifinalist for the BioLOGIC innovation award for early stage company working to advance human health in Kentucky, Ohio and Indiana. The next step of the award is community voting which comprises 25% toward selection of the finalist. I will greatly appreciate your voting for the finalist before May 15 by clinking the website below and “ CLICK HERE TO CAST YOUR VOTE” at the top of the page. Please vote here: https://lnkd.in/eK8tAX3 Also, please forward to your network.
